Skip to main content

The Globe and Mail

QLT profit gets boost from cancer drug sales

Drug-maker QLT Inc. says sales of its prostate cancer drug Eligard will grow faster than originally expected this year and already helped boost revenues and profit in the second quarter. The higher sales may also increase the company's chance of selling Eligard, which QLT put on the block many months agoGlobal sales of Eligard rose 12 per cent to $67.6-million (U.S.) in the April-June period compared to last year. QLT-T (TSX) rose 17 cents to $3.57.

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at